Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Objectives To evaluate the diagnostic accuracy of the Roche SARS-CoV-2 & Flu A/B Rapid Antigen Test at the point of care. Design Prospective diagnostic accuracy study. Setting 17 primary care practices in England. Participants 500 individuals with symptoms consistent with possible SARS-CoV-2 or influenza infection identified upon presentation to primary care or via medical note review. Primary and secondary outcome measures Sensitivity, specificity and predictive values, compared to a laboratory reference standard of real-time reverse transcription PCR, using samples collected using a combined nasal and oropharyngeal swab. Of 481 participants with available index and reference test results, 5.6% (27/481) were reference standard-positive for SARS-CoV-2, 11.4% (55/481) for Influenza A and 1.9% (9/481) for Influenza B. The sensitivity of the antigen test to detect SARSCoV-2 was 70.4% (19/27, 95% CI 49.6–86.2%) and specificity was 99.3% (451/454, 95%CI 98.1–99.9%). For Influenza A, sensitivity was 29.1% (16/55, 95% CI 17.6–42.9%) and specificity 98.6% (420/426, 97.0–99.5%), and for Influenza B, sensitivity was 22.2% (2/9, 2.8–60.0%) and specificity 98.1% (463/472, 96.4–99.1%). Conclusions In a primary care population of symptomatic individuals, the assay was highly specific and had moderate sensitivity to detect SARS-CoV-2, but did not detect the majority of influenza infections.

Original publication

DOI

10.1371/journal.pone.0329611

Type

Journal article

Journal

Plos One

Publication Date

01/08/2025

Volume

20